Affinity Asset Advisors, Llc Portfolio Stock Holdings
According to the SEC 13F filed on August 13, 2026, Affinity Asset Advisors, Llc disclosed 92 stock positions valued at approximately $2.04B as of quarter-end June 30, 2026. The largest holdings include ROIVANT SCIENCES LTD, APOGEE THERAPEUTICS INC, and SPYRE THERAPEUTICS INC.
- Report Period
- June 30, 2026
- No. of Stocks
- 92
- Portfolio Value
- $2.04B
Holdings by Sector
Affinity Asset Advisors, Llc Portfolio Holdings in Q2 2026
| Company | Symbol | Sector | Portfolio % | Shares | Change (Shares) | Change % | Value |
|---|---|---|---|---|---|---|---|
| ROIVANT SCIENCES LTD | ROIV | Healthcare | 6.49% | 3,750,000 | +950,000 | +33.93% | $132,712,500 |
| APOGEE THERAPEUTICS INC | APGE | Healthcare | 6.41% | 987,000 | -297,926 | -23.19% | $131,004,510 |
| SPYRE THERAPEUTICS INC | SYRE | Healthcare | 5.55% | 1,279,134 | - | - | $113,561,517 |
| XENON PHARMACEUTICALS INC | XENE | Healthcare | 4.71% | 1,595,000 | -80,000 | -4.78% | $96,274,200 |
| ERASCA INC | ERAS | Healthcare | 4.70% | 5,250,000 | -100,000 | -1.87% | $96,180,000 |
| INSMED INC | INSM | Healthcare | 3.39% | 650,000 | +170,000 | +35.42% | $69,303,000 |
| PRAXIS PRECISION MEDICINES I | PRAX | Healthcare | 3.03% | 185,000 | +15,000 | +8.82% | $61,936,150 |
| ALKERMES PLC | ALKS | Healthcare | 2.88% | 1,125,000 | -225,000 | -16.67% | $58,944,375 |
| ORUKA THERAPEUTICS INC | ORKA | Healthcare | 2.75% | 590,000 | +90,327 | +18.08% | $56,150,300 |
| ANAPTYSBIO INC | ANAB | Healthcare | 2.73% | 826,109 | -113,891 | -12.12% | $55,762,358 |
| AVALO THERAPEUTICS INC | AVTX | Healthcare | 2.62% | 2,900,000 | +1,559,160 | +116.28% | $53,592,000 |
| CYTOKINETICS INC | CYTK | Healthcare | 2.29% | 550,000 | -150,483 | -21.48% | $46,854,500 |
| REVOLUTION MEDICINES INC | RVMD | Healthcare | 2.29% | 250,000 | +150,000 | +150.00% | $46,820,000 |
| ABIVAX SA | ABVX | Healthcare | 2.15% | 330,000 | -75,000 | -18.52% | $43,975,800 |
| FIRST TRACKS BIOTHERAPEUTICS | TRAX | Healthcare | 2.00% | 2,032,012 | +2,032,012 | +100.00% | $40,884,081 |
| DIANTHUS THERAPEUTICS INC | DNTH | Healthcare | 1.91% | 400,000 | +50,000 | +14.29% | $38,992,000 |
| SUTRO BIOPHARMA INC | STRO | Healthcare | 1.90% | 1,172,487 | +102,968 | +9.63% | $38,926,568 |
| NUVALENT INC | NUVL | Healthcare | 1.66% | 275,000 | -25,000 | -8.33% | $33,962,500 |
| TREVI THERAPEUTICS INC | TRVI | Healthcare | 1.64% | 1,800,172 | -200,000 | -10.00% | $33,573,208 |
| OVID THERAPEUTICS INC | OVID | Healthcare | 1.33% | 10,144,562 | -491,756 | -4.62% | $27,288,872 |
| LEXEO THERAPEUTICS INC | LXEO | Healthcare | 1.32% | 5,807,611 | +757,400 | +15.00% | $27,034,429 |
| CELLDEX THERAPEUTICS INC NEW | CLDX | Healthcare | 1.27% | 700,000 | +200,000 | +40.00% | $26,047,000 |
| BELITE BIO INC | BLTE | Healthcare | 1.24% | 165,000 | +100,000 | +153.85% | $25,407,525 |
| ENLIVEN THERAPEUTICS INC | ELVN | Healthcare | 1.24% | 500,000 | -86,904 | -14.81% | $25,375,000 |
| NURIX THERAPEUTICS INC | NRIX | Healthcare | 1.15% | 967,620 | - | - | $23,474,461 |
| ALTO NEUROSCIENCE INC | ANRO | Healthcare | 1.10% | 850,000 | +350,000 | +70.00% | $22,431,500 |
| MADRIGAL PHARMACEUTICALS INC | MDGL | Healthcare | 1.05% | 40,000 | -15,000 | -27.27% | $21,478,000 |
| PROTAGONIST THERAPEUTICS INC | PTGX | Healthcare | 1.03% | 172,125 | - | - | $21,099,083 |
| MINERALYS THERAPEUTICS INC | MLYS | Healthcare | 0.99% | 750,000 | - | - | $20,235,000 |
| RELAY THERAPEUTICS INC | RLAY | Healthcare | 0.96% | 1,050,000 | +650,000 | +162.50% | $19,645,500 |
Showing 30 of 92 holdings in the latest reporting period.
Affinity Asset Advisors, Llc Options Holdings in Q2 2026
| Quarter | Symbol | Company | Option | Contracts | Notional Value |
|---|---|---|---|---|---|
| Q2 2026 | MRNA | Moderna, Inc. | PUT | 500,000 | $35,015,000 |
| Q2 2026 | MRNA | Moderna, Inc. | CALL | 475,000 | $33,264,250 |
| Q2 2026 | ARKG | ARK Genomic Revolution ETF | CALL | 750,000 | $31,545,000 |
| Q2 2026 | LLY | Eli Lilly and Company | CALL | 20,000 | $23,988,600 |
| Q2 2026 | OMER | Omeros Corporation | PUT | 1,411,300 | $13,421,463 |
| Q2 2026 | ALKS | Alkermes | CALL | 250,000 | $13,098,750 |
| Q2 2026 | QURE | uniQure N.V. | CALL | 200,000 | $9,212,000 |
| Q2 2026 | EVMN | Evommune, Inc. | PUT | 500,100 | $6,646,329 |
| Q2 2026 | SMMT | Summit Therapeutics Inc. | CALL | 100,000 | $1,457,000 |
Showing 9 of 9 options positions in the latest reporting period.
Notional value represents the total exposure of the options position.